6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Essential oils block cellular entry of SARS-CoV-2 delta variant

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aiming to fill a gap in the literature, we aimed to identify the most promising EOs blocking in vitro cellular entry of SARS-CoV-2 delta variant without conferring human cytotoxicity and provide insights into the influence of their composition on these activities. Twelve EOs were characterized by gas chromatography coupled to mass spectrometry. The antiviral and cytotoxicity activities were determined using the cell-based pseudoviral entry with SARS-CoV-2 delta pseudovirus and the XTT assay in HeLa cells expressing human angiotensin-converting enzyme 2 (HeLa ACE-2), respectively. Syzygium aromaticum, Cymbopogon citratus, Citrus limon, Pelargonium graveolens, Origanum vulgare, “ Illicium verum”, and Matricaria recutita showed EC 50 lowered or close to 1 µg/mL but also the lowest CC 50 (0.20–1.70 µg/mL), except “ I. verum” (30.00 µg/mL). Among these, “ I. verum”, C. limon, P. graveolens and S. aromaticum proved to be promising alternatives for SARS-CoV-2 delta variant inhibition (therapeutic index above 4), which possibly was related to the compounds (E)-anetole, limonene and beta-pinene, citronellol, and eugenol, respectively.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

          Abstract Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel’s largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine. Methods All persons who were newly vaccinated during the period from December 20, 2020, to February 1, 2021, were matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics. Study outcomes included documented infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), symptomatic Covid-19, Covid-19–related hospitalization, severe illness, and death. We estimated vaccine effectiveness for each outcome as one minus the risk ratio, using the Kaplan–Meier estimator. Results Each study group included 596,618 persons. Estimated vaccine effectiveness for the study outcomes at days 14 through 20 after the first dose and at 7 or more days after the second dose was as follows: for documented infection, 46% (95% confidence interval [CI], 40 to 51) and 92% (95% CI, 88 to 95); for symptomatic Covid-19, 57% (95% CI, 50 to 63) and 94% (95% CI, 87 to 98); for hospitalization, 74% (95% CI, 56 to 86) and 87% (95% CI, 55 to 100); and for severe disease, 62% (95% CI, 39 to 80) and 92% (95% CI, 75 to 100), respectively. Estimated effectiveness in preventing death from Covid-19 was 72% (95% CI, 19 to 100) for days 14 through 20 after the first dose. Estimated effectiveness in specific subpopulations assessed for documented infection and symptomatic Covid-19 was consistent across age groups, with potentially slightly lower effectiveness in persons with multiple coexisting conditions. Conclusions This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

            Countermeasures to prevent and treat COVID-19 are a global health priority. We enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate antibody responses, adapted our high-throughput antibody generation pipeline to rapidly screen over 1800 antibodies, and established an animal model to test protection. We isolated potent neutralizing antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. We showed that passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters, as revealed by maintained weight and low lung viral titers in treated animals. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              A generalization of the retention index system including linear temperature programmed gas—liquid partition chromatography

                Bookmark

                Author and article information

                Contributors
                luiztorresneto@ufrj.br
                marialuciaguerra@yahoo.com.br
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                30 November 2022
                30 November 2022
                2022
                : 12
                : 20639
                Affiliations
                [1 ]Center for Food Analysis (NAL), Technological Development Support Laboratory (LADETEC), Cidade Universitária, Rio de Janeiro, RJ 21941-598 Brazil
                [2 ]GRID grid.8536.8, ISNI 0000 0001 2294 473X, Laboratory of Advanced Analysis in Biochemistry and Molecular Biology (LAABBM), Department of Biochemistry, , Federal University of Rio de Janeiro (UFRJ), ; Cidade Universitária, Rio de Janeiro, RJ 21941-909 Brazil
                [3 ]GRID grid.8536.8, ISNI 0000 0001 2294 473X, Graduate Program in Food Science (PPGCAL), Institute of Chemistry (IQ), , Federal University of Rio de Janeiro (UFRJ), ; Cidade Universitária, Avenida Athos da Silveira Ramos, N. 149, Bloco A, 5° Andar, Rio de Janeiro, RJ 21941-909 Brazil
                [4 ]GRID grid.411173.1, ISNI 0000 0001 2184 6919, Graduate Program in Veterinary Hygiene (PPGHV), Faculty of Veterinary Medicine, , Fluminense Federal University (UFF), ; Vital Brazil Filho, Niterói, RJ 24220-000 Brazil
                [5 ]GRID grid.253205.3, ISNI 0000 0004 0387 4272, Science Department, , Borough of Manhattan Community College, The City University of New York, ; 199 Chambers Street, Science Department Room N699, New York, NY 10007 USA
                [6 ]GRID grid.250540.6, ISNI 0000 0004 0441 8543, Center for Biomedical Research, , Population Council, ; 1230 York Avenue, New York, NY 10065 USA
                [7 ]GRID grid.418068.3, ISNI 0000 0001 0723 0931, Graduate Program in Sanitary Surveillance (PPGVS), National Institute of Health Quality Control (INCQS), , Oswaldo Cruz Foundation (FIOCRUZ), ; Rio de Janeiro, RJ 21040-900 Brazil
                Article
                25342
                10.1038/s41598-022-25342-8
                9709744
                36450916
                8abba3e5-0243-4e01-8d24-c22e465c5f1b
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 August 2022
                : 29 November 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100002322, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior;
                Award ID: [88887.518752/2020-00]
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100004586, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro;
                Award ID: [E-26/200.891/2021], [E-26/010.000148/2020], and [E-26/201.790/2020]
                Award ID: [E-26/200.891/2021], [E-26/010.000148/2020], and [E-26/201.790/2020]
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100003593, Conselho Nacional de Desenvolvimento Científico e Tecnológico;
                Award ID: [313119/2020-1]
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                sars-cov-2,mass spectrometry,natural products
                Uncategorized
                sars-cov-2, mass spectrometry, natural products

                Comments

                Comment on this article